Coco Kou

Director of Finance/CFO at QHY GROUP

43 year

Consumer Services

Industrial Services

Health Technology

Profile

Coco Kou is currently the Chief Financial Officer at QHY Group and the Chief Financial & Accounting Officer at Four Leaf Acquisition Corp.
Prior to these roles, Ms. Kou served as the Chief Financial Officer at Xynomic Pharmaceuticals Holdings, Inc. from 2019 to 2021.
Ms. Kou holds an undergraduate degree and a graduate degree from Peking University, an MBA from the University of Hong Kong, London Business School, and Columbia Business School.

Coco Kou active positions

Companies	Position	Start
QHY GROUP	Director of Finance/CFO	-
FOUR LEAF ACQUISITION CORPORATION	Director of Finance/CFO	2021-12-31

All active positions of Coco Kou

Former positions of Coco Kou

Companies	Position	End
XYNOMIC PHARMACEUTICALS HOLDINGS, INC.	Director of Finance/CFO	2020-12-31

See the detail of Coco Kou's experience

Training of Coco Kou

Peking University	Graduate Degree
University of Hong Kong	Masters Business Admin
London Business School	Masters Business Admin
Columbia Business School	Masters Business Admin

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Coco Kou's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	2
QHY GROUP	Industrial Services
FOUR LEAF ACQUISITION CORPORATION	Finance

Private companies	1
Xynomic Pharmaceuticals Holdings, Inc. Xynomic Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Xynomic Pharmaceuticals Holdings, Inc. is a clinical stage best-in-class oncology therapeutics biopharmaceutical company. It engages in licensing, developing and commercializing oncology drug candidates in China, US, and rest of the world. Its current pipeline mainly consists of 3 drug candidates; Xynomic owns global exclusive development, manufacturing and commercialization rights to each of these. Its lead drug candidate abexinostat is in global potentially pivotal clinical trials against renal cell carcinoma and non-Hodgkin's lymphoma. The company was founded by Yinglin Mark Xu on October 7, 2016 and is headquartered in Shanghai, China.	Health Technology